Early neurological deterioration (END) following acute ischemic stroke (AIS) in patients treated with intravenous recombinant tissue-type plasminogen activator (IV-rtPA) is a common and prominent clinical issue that is strongly associated with patient dependency and death at 3 months after AIS (1, 2). Here, PLAT is linked to androgen insensitivity syndrome.